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of MR-proANP was performed in serum using sandwich im-
munoassay. The primary endpoint was functional outcome 
[assessed by the Glasgow Outcome Score (GOS)] and the 
secondary endpoints were mortality within 180 days after 
hemorrhagic stroke and influence of temperature on MR-
proANP. A favorable outcome was defined as GOS 4–5, and 
the patients were considered to have a poor outcome with 
a 180-day GOS score between 1 and 3.  Results: Analysis of 
MR-proANP was performed in 24 patients with spontaneous 
SAH and 22 patients with spontaneous ICH. MR-proANP was 
elevated on days 4 and 7 as compared to baseline levels (p < 
0.05 and p  < 0.001, respectively). High MR-proANP levels 
(>120 pmol/l) were associated with increased mortality and 
poor outcome (after 180 days; p < 0.05, respectively). There 
was no significant difference regarding MR-proANP serum 
concentrations between the endovascular and the control 
groups.  Conclusions: Increased levels of MR-proANP are in-
dependently associated with poor functional outcome and 
increased mortality after 180 days in patients with hemor-
rhagic stroke. Endovascular temperature control had no sig-
nificant influence on MR-proANP levels. 
 © 2014 S. Karger AG, Basel 
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 Abstract 
 Background: Atrial natriuretic peptide (ANP) is a well-known 
prognostic marker of outcome and mortality in patients with 
cardiovascular disease. Midregional proatrial natriuretic 
peptide (MR-proANP) is a stable fragment of the ANP precur-
sor hormone. As a prognostic marker after ischemic stroke, 
it reliably predicts poststroke mortality and functional out-
come. This study aimed to analyze the prognostic value of 
MR-proANP in patients with hemorrhagic stroke, i.e. sub-
arachnoid (SAH) and intracerebral hemorrhage (ICH).  Meth-
ods: MR-proANP was analyzed in patients with spontaneous 
SAH or spontaneous ICH. All patients were prospectively ran-
domized into two treatment arms: (1) a prophylactic normo-
thermia group with a target core temperature 36.5  °  C using 
endovascular cooling, and (2) a control group with conven-
tional stepwise predefined fever management using anti-
pyretic medication and surface cooling. Blood samples were 
obtained on admission and on days 4 and 7. Measurement 
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 Introduction 
 Hemorrhagic stroke, i.e. subarachnoid (SAH) and in-
tracerebral hemorrhage (ICH), is a devastating neurolog-
ical disease  [1–3] . Prognostic markers may improve risk 
stratification and allow early prognostication, both for 
functional outcome and mortality, thus improving indi-
vidual treatment and allocation of hospital and human 
resources.
 Atrial natriuretic peptide (ANP) is a prognostic mark-
er of cardiovascular-based mortality  [4] . Accounting for 
about 98% of all circulating natriuretic peptides, ANP is 
released from intracellular granules in atrial myocytes 
upon atrial dilation, with myocyte stretching through 
volume and blood pressure challenge being the most po-
tential stimulators  [5] . ANP-immunoreactive glial cells 
have been found in ischemic brain tissue, suggesting reg-
ulation of cerebral blood flow through ANP  [6] . More-
over, release of ANP from brain tissue has also been re-
ported during cerebral ischemia  [6, 7] .
 Assessment of circulating ANP is challenging since 
early destruction of this protein by endopeptidases leads 
to a short half-life  of 1–5 min  [5] . By contrast, the prohor-
mone proANP has a longer half-life  [8] . Midregional pro-
atrial natriuretic peptide (MR-proANP) is a stable frag-
ment of the ANP precursor hormone and is secreted in 
equimolar amounts to ANP  [9] .
 In patients with acute ischemic stroke, MR-proANP 
has been shown to reliably predict functional outcome 
and mortality  [4, 10, 11] . This study evaluates the prog-
nostic value of MR-proANP in SAH and ICH patients 
regarding functional (neurological) outcome, mortality 
after 6 months and stability of MR-proANP regarding 
novel targeted temperature measurements.
 Methods 
 Ethics Statement 
 The study was approved by the institutional review board of 
Innsbruck Medical University (protocol No. UN1734/AM1734a). 
According to Austrian law, written informed consent was obtained 
either before enrollment in competent patients or as soon as the 
patient regained competence. The informed consent procedures 
were approved by the institutional review board. All potential par-
ticipants, who declined to participate or otherwise did not partici-
pate, were eligible for treatment and were not disadvantaged in any 
other way by not participating in the study.
 Study Site and Participants 
 This study was designed as an extension of a prospective ran-
domized controlled trial on endovascular-based normothermia 
in patients with cerebrovascular disease and was performed at 
Innsbruck University Hospital, Austria, a 1,500-bed tertiary 
care hospital with approximately 74,000 admissions per year. 
The neurologic intensive care unit is a 10-bed neurocritical care 
unit admitting, on a nonelective basis, about 700 adults per year, 
with a significant proportion of the patients being diagnosed 
with SAH or ICH. A detailed description of the study population 
has been published previously  [12] . Patients were randomized 
into two treatment arms: (1) prophylactic endovascular-based 
controlled normothermia with a target temperature of 36.5   °   C 
(CoolGard 3000 and CoolLine devices; Zoll ® ), and (2) conven-
tional fever management strictly following a predefined proto-
col. Temperature control management including calculation of 
fever burden has been described in detail previously  [12] .
 Sample Collection and Measurement of MR-proANP 
 Analysis of MR-proANP was performed in the patients’ sera, 
collected at the time of enrollment as well as 4 and 7 days after ad-
mission to the neurologic intensive care unit using Sarstedt 
Monovette serum tubes. Data collection used in the present analy-
sis was done prospectively since the original design of the study 
included subgroup analysis of inflammatory parameters as an ad-
ditional endpoint. To minimize bias probably introduced by day-
time variation, blood drawing was done immediately after enroll-
ment and at 7 a.m. on the respective days thereafter. Serum was 
obtained by centrifugation at 1,500  g for 15 min after at least 
30 min of clotting time and stored at –20  °  C until use. MR-proANP 
was detected in serum from all patients with a sandwich immuno-
assay (Thermo Fisher BRAHMS, Hennigsdorf/Berlin, Germany), 
as described in detail elsewhere  [9] .
 Endpoints 
 The primary endpoint was functional outcome at 180 days after 
the acute event assessed by a dichotomized Glasgow Outcome 
Score (GOS; favorable outcome = GOS 4–5, poor outcome = GOS 
1–3). Secondary endpoints were mortality within 180 days after the 
acute event and dependency of temperature management. Follow-
up telephone interviews 180 days after the event were performed 
by a blinded trained physician with the patient or next of kin.
 Statistical Analyses 
 Baseline characteristics were compared using a t test (age, 
APACHE II score, body core temperature, BMI, fever burden), 
Fisher’s exact test (gender, treatment group, diagnosis) and Krus-
kal-Wallis test (Hunt and Hess grade, Glasgow Coma Scale). To 
eliminate the risk of a putative selection bias, baseline characteris-
tics were compared using a t test (age, APACHE II score, body core 
temperature, BMI, fever burden), Fisher’s exact test (gender, treat-
ment group, diagnosis) and Kruskal-Wallis test (Hunt and Hess 
grade, Glasgow Coma Scale).
 The Kolmogorov-Smirnov test was used to test for normal 
distribution of continuous variables. To analyze repeated mea-
surements of serum levels, a Wilcoxon signed-rank test or Fried-
man test was performed followed by Dunn’s test for multiple 
comparisons. The Mann-Whitney U test was performed for 
comparison between two groups (favorable vs. poor outcome, 
survivors vs. nonsurvivors); for more than two comparisons the 
Kruskal-Wallis test was used. In order to confirm the associa-
tion between MR-proANP and poor functional outcome/mor-
tality and test for important covariates (age, gender), general es-
timating equation models with a linear link function were cal-
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culated. Days after hemorrhage and GOS score were used as 
factors. Receiver operating curve analysis was used to evaluate 
the predictive value of MR-proANP serum levels regarding 
functional outcome and mortality. GOS values were dichoto-
mized for this approach to receive binary outcome measures. 
GOS was categorized into values for unfavorable outcome (GOS 
1–3, i.e. unable to live independently or worse) and favorable 
outcome (GOS 4–5, i.e. able to live independently). Data are pre-
sented as medians [interquartile range (IQR)] unless otherwise 
stated. A two-sided p value <0.05 was considered statistically 
significant. All statistical analyses were performed using the 
PASW 18.0 package (SPSS Inc., Chicago, Ill., USA) and the 
GraphPad Prism 5 software (GraphPad Prism Software Inc., San 
Diego, Calif., USA).
 Results 
 Baseline Characteristics 
 Excluding patients with ischemic stroke, 92 patients 
were eligible for this study. After preanalytical screening, 
workup of MR-proANP was not possible in another 46 
patients. A total number of 46 patients were included in 
the final analysis (demographic and clinical data of the 
study population are listed in  table 1 ). Of those, 24 pa-
tients were diagnosed with spontaneous SAH and 22 pa-
tients suffered from spontaneous ICH.
 Time Course of MR-proANP Serum Levels 
 MR-proANP serum levels showed a significant in-
crease throughout day 7 ( fig. 1 ). Baseline serum concen-
trations were lower (96.0 pmol/l, IQR: 63.8–130.9) com-
pared to days 4 (113.5 pmol/l, IQR: 77.0–167.2; p < 0.05) 
and 7 (140.8 pmol/l, IQR: 87.0–208.5; p < 0.001). There 
was no statistical difference between patients with SAH 
and ICH regarding MR-proANP serum levels. We did 
not find an association between MR-proANP concen-
trations and the presence of hypo- or hypernatremia, 
cardiac arrhythmia, or pulmonary edema (data not 
shown).
 Functional Outcome 
 Serum levels of MR-proANP on days 1 and 4 differed 
significantly between patients with favorable (GOS 4–5) 
and poor functional outcome (GOS 1–3) after 180 days 
[day 1: 69.0 pmol/l (IQR: 40.9–112.4) vs. 118.0 pmol/l 
(IQR: 65.3–138.2); day 4: 83.5 pmol/l (IQR: 61.1–113.5) 
vs. 154.5 pmol/l (IQR 110.3–216.5); p < 0.05]. Accord-
ingly, mean MR-proANP (days 1–7) was significantly 
higher in patients with an unfavorable outcome [87.3 
pmol/l (IQR: 40.7–120.1) vs. 124.6 pmol/l (IQR 97.3–
192.6); p < 0.05] (fig. 2). Receiver operating characteris-
tics curve analysis revealed AUC values for MR-proANP 
on day 1 of 0.67 (95% CI: 0.49–0.84) and 0.77 (95% CI: 
0.55–0.99) for mean MR-proANP from day 1 to day 7 
(p < 0.05). A MR-proANP threshold of 120 pmol/l  [13] 
had a sensitivity of 50% and specificity of 21% for day 1, 
and a sensitivity of 78% and specificity 80% for mean 
 MR-proANP.
Table 1.  Baseline characteristics of the study population
ICH SAH
Subjects, n 22 24
Females, n (%) 13 (59) 7 (29)
Age, years 59.3±12.0 55.8±15.1
BMI, kg/m2 26.6±3.6 25.8±3.0
GOS
1 3 8
2 1 1
3 6 1
4 8 2
5 1 9
Antipyretic medication
NSAIDs 16 15
No NSAIDs 6 9
 Values represent n (%) or means ± SD. NSAIDs = Nonsteroidal 
anti-inflammatory drugs.
1 4
Days after enrollment
*
**
***
MR
-pr
oA
NP
 (p
mo
l/l)
0
200
400
600
7
 Fig. 1. Temporal development of MR-proANP. Temporal profile 
of MR-proANP serum levels on days 1, 4 and 7 after enrollment. 
For comparison between single days, the Wilcoxon signed-rank 
test was used.  *  p < 0.05,  * *  p < 0.01,  * * *  p < 0.001. 
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 Mortality 
 A comparison of survivors (n = 29) and nonsurvivors 
(n = 11) showed elevated MR-proANP levels on days 4 and 
7 in nonsurvivors [day 4: 181.7 pmol/l (IQR: 113.8–220.0) 
vs. 98.9 pmol/l (IQR: 63.8–154.9); day 7: 243.8 pmol/l 
(IQR: 132.6–296.9) vs. 112.5 pmol/l (IQR 74.2–165.5); p < 
0.05; fig. 3 ]. The general estimating equation model for the 
association between mortality and serum concentrations 
of natriuretic peptide underlined this finding (p < 0.001). 
When using the receiver operating characteristics curve 
analysis for prediction of mortality, area under the curve 
values were 0.62 (95% CI: 0.42–0.82) and 0.92 (95% CI: 
0.77–1.0) for baseline MR-proANP and mean MR- 
proANP (from day 1 to day 7), respectively (p < 0.05). A 
MR-proANP threshold of 120 pmol/l had a sensitivity of 
64% and specificity of 59% for day 1, and a sensitivity of 
100% and specificity of 67% for mean MR-proANP.
 Patients with a high Acute Physiology and Chronic 
Health Evaluation (APACHE) II score (>19) were com-
pared with those showing lower APACHE II scores ( ≤ 19) 
on admission. This analysis revealed significantly elevat-
ed MR-proANP serum levels in patients with APACHE 
II scores >19 (p < 0.05).
 Temperature Management 
 When comparing endovascular temperature control 
regimen patients and the control group, no statistical 
 difference in MR-proANP concentrations was found, 
 although fever burden was significantly lower in the 
 patients undergoing endovascular temperature control 
(p < 0.0001).
 Discussion 
 In this study, MR-proANP levels were analyzed in 46 
patients with severe spontaneous SAH or ICH requiring 
intensive care treatment. The main findings were: (1) MR-
proANP significantly increases over time in SAH and ICH 
patients compared to baseline levels, and (2) increased se-
rum levels of MR-proANP are associated with poor func-
tional outcome and mortality after 180 days (GOS 1–3).
 ANP has been recognized as a predictor of functional 
outcome and mortality in patients with cardiovascular 
disease  [14–16] . Recently, results of a prospective study 
in patients with ischemic stroke showed MR-proANP to 
be a strong predictor of functional outcome and post-
stroke mortality  [10] . Patients with poor functional out-
come as assessed by the modified Rankin scale revealed 
significantly higher MR-proANP serum levels compared 
with patients with favorable functional outcome  [10] .
 To the best of our knowledge, there are no reports 
about MR-proANP levels in patients with hemorrhagic 
stroke. We found a significant association of MR- proANP 
serum concentrations with poor outcome and mortality 
in SAH and ICH patients. Natriuretic peptides have been 
*
*
MR
-pr
oA
NP
 (p
mo
l/l)
0
50
100
150
200
250
1 4
Days after enrollment
7
Favorable outcome
Poor outcome
*
*
MR
-pr
oA
NP
 (p
mo
l/l)
0
100
200
300
1 4
Days after enrollment
7
Survivor
Nonsurvivor
 Fig. 2. MR-proANP and functional outcome. MR-proANP serum 
concentrations in patients with favorable (GOS 4–5) and poor 
(GOS 1–3) functional outcome, compared using the Mann-Whit-
ney U test.  *  p < 0.05. 
 Fig. 3. MR-proANP in survivors vs. nonsurvivors. MR-proANP 
serum levels are significantly elevated in nonsurvivors on days 4 
and 7 (p < 0.05). A Mann-Whitney-U test was used for comparison 
between groups.  *  p < 0.05. 
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shown to be elevated in patients with SAH and have been 
found to be associated with a decreased level of con-
sciousness  [17, 18] . Data from experimental studies sug-
gest that cerebral ischemia induces ANP release  [6, 7] . In 
patients with ICH, higher levels of brain natriuretic pep-
tide, another member of the natriuretic peptide family, 
have been reported to be associated with functional neu-
rological outcome  [19] .
 Natriuretic peptides are involved in hemodynamic 
regulation, fluid and volume homeostasis increasing di-
uresis and natriuresis  [20] . ANP release is triggered by 
volume challenge of the cardiac atrium  [20] . Alterations 
of ANP levels in hemorrhagic stroke patients seem to be 
multifactorial: cardiac abnormalities are common in pa-
tients with (severe) SAH and ICH  [21–24] .
 Clinical symptoms and electrocardiographic changes 
may mimic (ischemic) myocardial injury  [25] . However, 
this effect is rather attributable to increased catecholamine 
release due to cerebral injury than coronary stenosis  [22, 
25] . Natriuretic peptides reduced circulating levels of cat-
echolamines in animal studies  [26] . Upon sympathoadre-
nal stimulation they act as counterregulators in response 
to myocardial injury  [5] . Thus, increased sympathetic ac-
tivation, which has been observed in patients with spon-
taneous SAH and poor outcome, may directly influence 
ANP release  [27] . In addition to neurohumoral effects, 
ANP increase may be triggered by therapeutic regulation 
of fluid balance and systemic vascular resistance  [5] .
 Increased sympathetic activation, which has been ob-
served in patients with spontaneous SAH and poor out-
come, may directly influence ANP release  [27] . In addi-
tion to neurohumoral effects, ANP increase may be trig-
gered by therapeutic regulation of fluid balance and 
systemic vascular resistance  [5] .
 Temperature modulation in this study was performed 
using endovascular temperature control and administra-
tion of antipyretic medication plus surface cooling. Strict 
temperature control and adherence to a predefined target 
temperature were achieved in the endovascular group us-
ing a catheter-based heat exchange system. Despite sig-
nificant differences regarding fever burden in the two 
treatment arms, there was no difference in MR-proANP 
serum levels  [12] . This indicates that MR-proANP re-
mains a stable biomarker even under novel temperature 
modulations. These results suggest that MR-proANP is a 
reliable marker of poor outcome, including mortality, 
even in patients under targeted temperature control. This 
is of utmost importance since the reliability of biomarkers 
under targeted temperature modulation has been dis-
cussed controversially recently  [28–30] .
 Several limitations need to be considered when inter-
preting our results. As the sample size was small, adjust-
ment for multiple potential confounders was not possi-
ble. Only a subgroup of patients was included in this final 
analysis. However, a putative selection bias is unlikely as 
comparison of baseline parameters of the respective 
groups did not reveal significant differences, with the ex-
ception of sex. This is a hypothesis-generating study 
showing for the first time that an elevation of MR- proANP 
serum levels is significantly associated with poor outcome 
in hemorrhagic stroke patients and might serve even ear-
ly after SAH onset as a reliable predictor of functional 
outcome in this patient population.
 Conclusions 
 Timely prognostication and prediction of long-term 
outcome is especially important in patients with hemor-
rhagic stroke as it allows for optimization of acute care 
and risk stratification. Elevation of MR-proANP in pa-
tients with hemorrhagic stroke might allow early diagno-
sis of patients at risk for hemodynamic instability and 
multiorgan dysfunction, finally leading to unfavorable 
outcome.
 Disclosure Statement 
 Measurement of MR-proANP was performed by BRAHMS 
AG. BRAHMS AG was neither involved in the study design, col-
lection, analysis, and interpretation of data nor writing of the 
reports. BRAHMS AG did not suppress any data or outcome 
analysis carried out as predefined in the study protocol.
 Marleen Seiler is an employee of Thermo Fisher Scientific. 
Thermo Scientific BRAHMS, Hennigsdorf, Germany provided all 
MR-proANP assays. This did not alter the authors’ adherence to 
all the  Cerebrovascular Diseases policies on sharing data and ma-
terials. 
 References  1 Qureshi AI, Tuhrim S, Broderick JP, Batjer 
HH, Hondo H, Hanley DF: Spontaneous in-
tracerebral hemorrhage. N Engl J Med 2001; 
 344: 1450–1460. 
 2 Suarez JI, Tarr RW, Selman WR: Aneurysmal 
subarachnoid hemorrhage. N Engl J Med 
2006; 354: 387–396. 
 3 Broessner G, Helbok R, Lackner P, Mitter-
berger M, Beer R, Engelhardt K, Brenneis C, 
Pfausler B, Schmutzhard E: Survival and long-
term functional outcome in 1,155 consecutive 
neurocritical care patients. Crit Care Med 
2007; 35: 2025–2030. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
9.
12
6.
78
.1
7 
- 1
2/
18
/2
01
5 
10
:1
5:
38
 P
M
 MR-proANP in Hemorrhagic Stroke Cerebrovasc Dis 2014;37:128–133
DOI: 10.1159/000357215
133
 4 Wang TJ, Larson MG, Levy D, Benjamin EJ, 
Leip EP, Omland T, Wolf PA, Vasan RS: Plas-
ma natriuretic peptide levels and the risk of 
cardiovascular events and death. N Engl J 
Med 2004; 350: 655–663. 
 5 Suttner SW, Boldt J: Natriuretic peptide sys-
tem: physiology and clinical utility. Curr 
Opin Crit Care 2004; 10: 336–341. 
 6 Nogami M, Shiga J, Takatsu A, Endo N, Ishi-
yama I: Immunohistochemistry of atrial na-
triuretic peptide in brain infarction. Histo-
chem J 2001; 33: 87–90. 
 7 Giuffrida R, Bellomo M, Polizzi G, Malatino 
LS: Ischemia-induced changes in the immuno-
reactivity for endothelin and other vasoactive 
peptides in the brain of the Mongolian gerbil. 
J Cardiovasc Pharmacol 1992; 20(Suppl 12): 
S41–S44. 
 8 Davidson NC, Coutie WJ, Struthers AD: N-
terminal proatrial natriuretic peptide and 
brain natriuretic peptide are stable for up to 
6 hours in whole blood in vitro. Circulation 
1995; 91: 1276–1277. 
 9 Morgenthaler NG, Struck J, Thomas B, Berg-
mann A: Immunoluminometric assay for the 
midregion of pro-atrial natriuretic peptide 
in human plasma. Clin Chem 2004; 50: 234–
236. 
 10 Katan M, Fluri F, Schuetz P, Morgenthaler 
NG, Zweifel C, Bingisser R, Kappos L, Steck 
A, Engelter ST, Müller B, Christ-Crain M: 
Midregional pro-atrial natriuretic peptide 
and outcome in patients with acute ischemic 
stroke. J Am Coll Cardiol 2010; 56: 1045–
1053. 
 11 Makikallio AM, Makikallio TH, Korpelainen 
JT, Vuolteenaho O, Tapanainen JM, Ylitalo K, 
Sotaniemi KA, Huikuri HV, Myllyla VV: Na-
triuretic peptides and mortality after stroke. 
Stroke 2005; 36: 1016–1020. 
 12 Broessner G, Beer R, Lackner P, Helbok R, 
Fischer M, Pfausler B, Rhorer J, Küppers-
Tiedt L, Schneider D, Schmutzhard E: Pro-
phylactic, endovascularly based, long-term 
normothermia in ICU patients with severe 
cerebrovascular disease: bicenter prospec-
tive, randomized trial. Stroke 2009; 40:e657–
e665. 
 13 Daniels LB, Clopton P, Potocki M, Mueller C, 
McCord J, Richards M, Hartmann O, Anand 
IS, Wu AH, Nowak R, Peacock WF, Poni-
kowski P, Mockel M, Hogan C, Filippatos GS, 
Di Somma S, Ng L, Neath SX, Christenson R, 
Morgenthaler NG, Anker SD, Maisel AS: In-
fluence of age, race, sex, and body mass index 
on interpretation of midregional pro atrial 
natriuretic peptide for the diagnosis of acute 
heart failure: results from the BACH multina-
tional study. Eur J Heart Fail 2012; 14: 22–31. 
 14 Schnabel RB, Schulz A, Messow CM, Lubos E, 
Wild PS, Zeller T, Sinning CR, Rupprecht HJ, 
Bickel C, Peetz D, Cambien F, Kempf T, Wol-
lert KC, Benjamin EJ, Lackner KJ, Munzel TF, 
Tiret L, Vasan RS, Blankenberg S: Multiple 
marker approach to risk stratification in pa-
tients with stable coronary artery disease. Eur 
Heart J 2010; 31: 3024–3031. 
 15 Kruger S, Papassotiriou J, Marre R, Richter K, 
Schumann C, von Baum H, Morgenthaler 
NG, Suttorp N, Welte T: Pro-atrial natriuret-
ic peptide and pro-vasopressin to predict se-
verity and prognosis in community-acquired 
pneumonia: results from the German compe-
tence network CAPNETZ. Intensive Care 
Med 2007; 33: 2069–2078. 
 16 von Haehling S, Jankowska EA, Morgenthaler 
NG, Vassanelli C, Zanolla L, Rozentryt P, 
Filippatos GS, Doehner W, Koehler F, Papas-
sotiriou J, Kremastinos DT, Banasiak W, 
Struck J, Ponikowski P, Bergmann A, Anker 
SD: Comparison of midregional pro-atrial 
natriuretic peptide with N-terminal pro-B-
type natriuretic peptide in predicting survival 
in patients with chronic heart failure. J Am 
Coll Cardiol 2007; 50: 1973–1980. 
 17 Wijdicks EF, Schievink WI, Burnett JC Jr: Na-
triuretic peptide system and endothelin in an-
eurysmal subarachnoid hemorrhage. J Neu-
rosurg 1997; 87: 275–280. 
 18 Nakamura T, Okuchi K, Matsuyama T, Fuku-
shima H, Seki T, Konobu T, Nishio K: Clinical 
significance of elevated natriuretic peptide 
levels and cardiopulmonary parameters after 
subarachnoid hemorrhage. Neurol Med Chir 
(Tokyo) 2009; 49: 185–191, discussion 191–
192. 
 19 James ML, Blessing R, Phillips-Bute BG, Ben-
nett E, Laskowitz DT: S100B and brain natri-
uretic peptide predict functional neurological 
outcome after intracerebral haemorrhage. 
Biomarkers 2009;14: 388–394. 
 20 Levin ER, Gardner DG, Samson WK: Natri-
uretic peptides. N Engl J Med 1998; 339: 321–
328. 
 21 Hasegawa K, Fix ML, Wendell L, Schwab K, 
Ay H, Smith EE, Greenberg SM, Rosand J, 
Goldstein JN, Brown DF: Ischemic-appearing 
electrocardiographic changes predict myocar-
dial injury in patients with intracerebral hem-
orrhage. Am J Emerg Med 2012; 30: 545–552. 
 22 Lee VH, Oh JK, Mulvagh SL, Wijdicks EF: 
Mechanisms in neurogenic stress cardiomy-
opathy after aneurysmal subarachnoid hem-
orrhage. Neurocrit Care 2006; 5: 243–249. 
 23 Temes RE, Tessitore E, Schmidt JM, Naidech 
AM, Fernandez A, Ostapkovich ND, Frontera 
JA, Wartenberg KE, Di Tullio MR, Badjatia N, 
Connolly ES, Mayer SA, Parra A: Left ventric-
ular dysfunction and cerebral infarction from 
vasospasm after subarachnoid hemorrhage. 
Neurocrit Care 2010; 13: 359–365. 
 24 van Bree MD, Roos YB, van der Bilt IA, Wilde 
AA, Sprengers ME, de Gans K, Vergouwen 
MD: Prevalence and characterization of ECG 
abnormalities after intracerebral hemor-
rhage. Neurocrit Care 2010; 12: 50–55. 
 25 Jespersen CM, Fischer Hansen J: Myocardial 
stress in patients with acute cerebrovascular 
events. Cardiology 2008; 110: 123–128. 
 26 Tota B, Cerra MC, Gattuso A: Catechol-
amines, cardiac natriuretic peptides and 
chromogranin A: evolution and physiopa-
thology of a ‘whip-brake’ system of the endo-
crine heart. J Exp Biol 2010; 213: 3081–3103. 
 27 Moussouttas M, Huynh TT, Khoury J, Lai 
EW, Dombrowski K, Pello S, Pacak K: Cere-
brospinal fluid catecholamine levels as pre-
dictors of outcome in subarachnoid hemor-
rhage. Cerebrovasc Dis 2012; 33: 173–181. 
 28 Oddo M: Prognostication after cardiac arrest: 
time to change our approach. Resuscitation 
2012; 83: 149–150. 
 29 Rossetti AO, Oddo M, Logroscino G, Kaplan 
PW: Prognostication after cardiac arrest and 
hypothermia: a prospective study. Ann Neu-
rol 2010; 67: 301–307. 
 30 Storm C, Nee J, Jorres A, Leithner C, Hasper 
D, Ploner CJ: Serial measurement of neuron 
specific enolase improves prognostication in 
cardiac arrest patients treated with hypother-
mia: a prospective study. Scand J Trauma Re-
susc Emerg Med 2012; 20: 6. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
14
9.
12
6.
78
.1
7 
- 1
2/
18
/2
01
5 
10
:1
5:
38
 P
M
